Form Type:  8-K
Filing Date:  6/22/2020 
CIK:  0001673772 
Address:  561 ECCLES AVENUE 
City, State, Zip:  SOUTH SAN FRANCISCO, California 94080 
Telephone:  (650) 489-9000 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
-0.14 (-0.67%)  
Trade Time: 
Jan 15  
Market Cap: 
Trade RAPT now with

© 2021  
Description of Business
We are a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing our proprietary drug discovery and development engine, we are developing highly selective small molecules designed to modulate the critical immune responses underlying these diseases. We have discovered and advanced into clinical development two unique drug candidates each targeting C-C motif chemokine receptor 4 ("CCR4"): FLX475 for the treatment of a range of tumors, and RPT193 for the treatment of allergic inflammatory diseases. We are also pursuing a range of targets, including general control nonderepressible 2 ("GCN2") and hematopoietic progenitor kinase 1 ("HPK1"), that are in the discovery stage of development.
Register and access this filing in:     
  FORM 8-K
      Item 5.07 Submission of Matters to a Vote of Security Holders.